New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief
Not yet recruiting
This Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC